Agents in clinical development for the treatment of chronic hepatitis B

Expert Opinion on Investigational Drugs

Volumn 12, Issue 8, 2003, Pages 1281-1295

  Raney, Anneke K ^a   Hamatake, Robert K ^b   Hong, Zhi ^b  

^a Ribapharm Inc   (United States)

^b NONE

Author keywords

Adefovir; Antiviral; Antiviral resistance; Clevudine; Elvucitabine; Emtricitabine; Entecavir; Hapavir B; Hepatitis B virus; Interferon; Lamivudine; Nucleoside; Telbivudine; Valtorcitabine; Viraemia

Indexed keywords

1 DEOXYNOJIRIMYCIN; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CLEVUDINE; CYTOCHROME P450 3A4; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; REMOFOVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; UNCLASSIFIED DRUG; VALTORCITABINE; VIRUS DNA; VIRUS ENZYME;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; ERADICATION THERAPY; EXPECTATION; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INHIBITION KINETICS; KIDNEY DISEASE; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MONOTHERAPY; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; TREATMENT OUTCOME;

EID: 0041633542     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.8.1281     Document Type: Review

References (114)

1. ROBINSON WS: Hepatitis B virus and hepatitis D virus. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, R Dolin (Eds), Churchill Livingstone, New York (1995):1406-1439.
2. LEE WM: Hepatitis B virus infection. N. Engl. J. Med. (1997) 337:1733-1745.
3. DELANEY WE, BARTHOLOMEUSZ A, LOCARNINI SA: Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin. Investig. Drugs (2002) 11:169-187.
4. KLINGMULLER U, SCHALLER H: Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J. Virol. (1993) 67:7414-7422.
5. TUTTLEMAN JS, POURCEL C, SUMMERS J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 47:451-460.
6. MILICH DR, JONES JE, HUGHES JL et al.: Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. USA (1990) 87:6599-6603.
7. LANFORD RE, NOTVALL L, LEE H, BEAMES B: Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. (1997) 71:2996-3004.
8. SUMMERS J: The replication cycle of hepatitis B viruses. Cancer (1988) 61:1957-1962.
9. GANEM D: Hepadnaviridae and their replication. In: Fields Virology. BN Fields, DM Knipe, PM Howley et al. (Eds), Lippincott-Raven Publishers, Philadelphia, USA (1996):2703-2737.
10. NASSAL M: Hepatitis B virus replication: novel roles for virus-host interactions. Intervirology (1999) 42:100-116.
11. SUMMERS J, SMITH PM, HUANG MJ, YU MS: Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus. J. Virol. (1991) 65:1310-1317.
12. SUMMERS J, SMITH PM, HORWICH AL: Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. (1990) 64:2819-2824.
13. SELLS MA, CHEN ML, ACS G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA (1987) 84:1005-1009.
14. DELANEY WE, ISOM HC: Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology (1998) 28:1134-1146.
15. DELANEY WE, MILLER TG, ISOM HC: Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob. Agents Chemother. (1999) 43:2017-2026.
16. SEIFER M, HAMATAKE RK, COLONNO RJ, STANDRING DN: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. (1998) 42:3200-3208.
17. DERES K, SCHRODER CH, PAESSENS A et al.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science (2003) 299:893-896.
18. WEBER O, SCHLEMMER KH, HARTMANN E et al.: Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. (2002) 54:69-78.
19. BLOCK TM, LU X, PLATT FM et al.: Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA (1994) 91:2235-2239.
20. LU X, MEHTA A, DWEK R, BUTTERS T, BLOCK T: Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology (1995) 213:660-665.
21. MEHTA A, CARROUEE S, CONYERS B et al.: Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology (2001) 33:1488-1495.
22. CHISARI FV, FERRARI C: Hepatitis B virus immunopathogenesis. Ann. Rev. Immunol. (1995) 13:29-60.
23. MAHONEY FJ, KANE M: Hepatitis B vaccine. In: Vaccines. SA Plotkin, WA Orenstein (Eds), W.B. Saunders Company, Philadelphia, USA (1999):158-182.
24. BEASLEY RP, HWANG LY, LEE GC et al.: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet (1983) 2:1099-1102.
25. ODA T: Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan. Jpn. J. Cancer Res. (1999) 90:1051-1060.
26. MILICH DR, SCHODEL F, HUGHES JL, JONES JE, PETERSON DL: The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J. Virol. (1997) 71:2192-2201.
27. PETERS M: Mechanisms of action of interferons. Semin. Liver Dis. (1989) 9:235-239.
28. CARRENO V, ZEUZEM S, HOPF U et al.: A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J. Hepatol. (2000) 32:317-324.
29. MUTCHNICK MG, LINDSAY KL, SCHIFF ER et al.: Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J. Viral. Hepat. (1999) 6:397-403.
30. CHAN HL, TANG JL, TAM W, SUNG JJ: The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther. (2001) 15:1899-1905.
31. CHIEN RN, LIAW YF, CHEN TC, YEH CT, SHEEN IS: Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology (1998) 27:1383-1387.
32. MICHEL ML: Prospects for active immunotherapies for hepatitis B virus chronic carriers. Res. Virol. (1997) 148:95-99.
33. POL S, NALPAS B, DRISS F et al.: Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. (2001) 34:917-921.
34. HEATHCOTE J, MCHUTCHISON J, LEE S et al.: A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology (1999) 30:531-6.
35. PANCHOLI P, LEE DH, LIU Q et al.: DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology (2001) 33:448-454.
36. KORENMAN J, BAKER B, WAGGONER J et al.: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. (1991) 114:629-634.
37. PERRILLO RP, SCHIFF ER, DAVIS GL et al.: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1990) 323:295-301.
38. WONG DK, CHEUNG AM, O'ROURKE K et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. (1993) 119:312-323.
39. HOOFNAGLE JH, DI BISCELGIE AM: Drug therapy: the treatment of chronic viral hepatitis. N. Engl. J. Med. (1997) 336:347-356.
40. GALAN MV, BOYCE D, GORDON SC: Current pharmacotherapy for hepatitis B infection. Expert Opin. Pharmacother. (2001) 2:1289-1298.
41. LAI CL, CHIEN RN, LEUNG NW et al.: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. (1998) 339:61-68.
42. DIENSTAG J, SCHIFF E, WRIGHT T et al.: Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis B e-antigen (HBeAg) seroconversion. Digestive Disease Week (1998) 114:A1235. (Abstract)
43. TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology (1999) 29:889-896.
44. SCHIFF E, KARAYALCIN I, GRIMM R, et al.: A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology (1998) 28:388A.
45. DIENSTAG JL, SCHIFF ER, WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. (1999) 341:1256-1263.
46. NEVENS F. MAIN J, HONKOOP P et al.: Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology (1997) 113:1258-1263.
47. LAI CL, LEUNG N, TEO EK et al.: International multicenter trial of LdT (telbivudine), alone and in combination with lamivudine, for chronic hepatitis B: an interim analysis. Hepatology (2002) 36:301A.
48. LEUNG NW, LAI CL, CHANG TT et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (2001) 33:1527-1532.
49. LIAW YF, LEUNG NW, CHANG TT et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 119:172-180.
50. HONKOOP P, NIESTERS HG, DE MAN RA, OSTERHAUS AD, SCHALM SW: Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. (1997) 26:1393-1395.
51. HADZIYANNIS SJ, VASSILOPOULOS D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 34:617-624.
52. LIAW YF, CHIEN RN, YEH CT, TSAI SL, CHU CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 30:567-572.
53. SANTANTONIO T, MAZZOLA M, IACOVAZZI T et al.: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. (2000) 32:300-306.
54. MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. (2003) 348:808-816.
55. HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. (2003) 348:800-807.
56. WILLEMS B, LAU GK, LEUNG N et al.: Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52 week results. Antiviral Ther. (2002) 7:L111.
57. PETERS M, HANN HW, MARTIN P et al.: Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis. J. Hepatology (2002) 36:374A.
58. DELANEY WE, EDWARDS R, COLLEDGE D et al.: Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob. Agents Chemother. (2001) 45:1705-1713.
59. YANG H, WESTLAND CE, DELANEY WE et al.: Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology (2002) 36:464-473.
60. GIBBS CS, XIONG S, YANG H et al.: Resistance surveillance in HBeAg- chronic hepatitis B patients (CHB) treated with adefovir dipivoxil (ADV) for two years. Antiviral Res. (2003) 57:A43.
61. FISHER EJ, CHALONER K, COHN DL et al.: The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease. a randomized, placebo-controlled trial. AIDS (2001) 15:1695-1700.
62. REDDY KR, WRIGHT TL, POCKROS PJ et al.: Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 33:433-438.
63. COOKSLEY G. 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia (2003).
64. YAMANAKA G, WILSON T, INNAIMO S et al.: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. (1999) 43:190-193.
65. INNAIMO SF, SEIFER M, BISACCHI GS et al.: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. (1997) 41:1444-1448.
66. GENOVESI EV, LAMB L, MEDINA I et al.: Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. (1998) 42:3209-3217.
67. COLONNO RJ, GENOVESI EV, MEDINA I et al.: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. (2001) 184:1236-1245.
68. MARION PI, SALAZAR FH, WINTERS MA, COLONNO RJ: Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. (2002) 46:82-88.
69. ONO SK, KATO N, SHIRATORI Y et al.: The polymerase L528M mutation cooperates with nucleoside binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. (2001) 107:449-455.
70. LEVINE S, HERNANDEZ D, YAMANAKA G et al.: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. (2002) 46:2525-2532.
71. TASSOPOULOS NC, HADZIYANNIS S, CIANCIARA J et al.: Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology (2001) 34:340A.
72. LAI CL, ROSMAWATI M, LAO J et al.: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 123:1831-1838.
73. HONKOOP P, DE MAN RA: Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin. Investig. Drugs (2003) 12:683-688.
74. DE MAN RA, WOLTERS LM, NEVENS F et al.: Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 34:578-582.
75. CHANG TT, HADZIYANNIS S, CIANCIARA J et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology (2002) 36:300A.
76. DOONG SL, TSAI CH, SCHINAZI RF, LIOTTA DC, CHENG YC: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA (1991) 88:8495-8499.
77. FURMAN PA, DAVIS M, LIOTTA DC et al.: The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. (1992) 36:2686-2692.
78. FENG JY, SHI J, SCHINAZI RF, ANDERSON KS: Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP FASEB J. (1999) 13:1511-1517.
79. KORBA BE, SCHINAZI RF, COTE P, TENNANT BC, GERIN JL: Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. (2000) 44:1757-1760.
80. LADNER SK, MILLER TJ, OTTO MJ, KING RW: The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir. Chem. Chemother. (1998) 9:65-72.
81. LEUNG N, GISH R, WANG C et al.: A randomized, double-blind, comparison of 3 doses of emtricitabine (FTC) in patients with chronic hepatitis B (CHB) given 48 weeks of treatment (FTCB-102). Hepatology (2001) 34:349A
82. MOMMEJA-MARIN H, LEUNG N, GISH R et al.: Antiviral activity and incidence of resistance after treatment for two years with emtricitabine in patients with chronic hepatitis B. 42nd ICAAC Abstracts (2002):426.
83. GISH R, LEUNG N, WANG C et al.: Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. Hepatology (2002) 36:372A.
84. HERNANDEZ-SANTIAGO B, PLACIDI L, CRETTON-SCOTT E et al.: Pharmacology of beta-L-thymidine and beta-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. (2002) 46:1728-1733.
85. BRYANT ML, BRIDGES EG, PLACIDI L et al.: Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. (2001) 45:229-235.
86. STANDRING DN, BRIDGES EG, PLACIDI L et al.: Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. (2001) 12:119-129.
87. SEIFER M, ZHOU F, FARAJ A et al.: In vitro studies on the mechanism of action of L-nucleoside inhibitors of hepatitis B virus replication reveal differences between LdT and lamivudine. Hepatology (2001) 34:635A.
88. TENNANT B, MENNE S, BALDWIN BH et al.: Antiviral activities of beta-L-thymidine (LdT), Val-beta-L-2′-deoxycytidine (val-LdC), and lamivudine alone and in combination in a 12 week, oral dose study using the woodchuck model of chronic hepatitis B virus infection. Frontiers in Drug Development for Viral Hepatitis, Maui, HI, USA (2001).
89. BROWN N: Progress in the clinical development of LdT (telbivudine) and Val-LdC (valtorcitabine), for treatment of patients with chronic hepatitis B. 4th International Antiviral Drug Discovery and Development Summit, Princeton, NJ, USA (2003).
90. LIM SG, YOUNG DY, YUEN M-F et al.: Safety and antiviral effects of val-LdC and LdT in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. (2002) 17:A26.
91. YUEN MF, SABLON E, HUI CK et al.: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology (2001) 34:785-791.
92. AGUESSE-GERMON S, LIU SH, CHEVALLIER M et al.: Inhibitory effect of 2′-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob. Agents Chemother. (1998) 42:369-376.
93. BALAKRISHNA PAI S, LIU SH, ZHU YL, CHU CK, CHENG YC: Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob. Agents Chemother. (1996) 40:380-386.
94. PEEK SF, COTE PJ, JACOB JR et al.: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology (2001) 33:254-266.
95. CHONG Y, CHU CK: Understanding the unique mechanism of L-FMAU (Clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg. Med. Chem. Lett. (2002) 12:3459-3462.
96. CHIN R, SHAW T, TORRESI J et al.: In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. (2001) 45:2495-2501.
97. WITCHER JW, BOUDINOT FD, BALDWIN BH et al.: Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks. Antimicrob. Agents Chemother. (1997) 41:2184-2187.
98. BLUM MR, CHITTICK G, WANG LH, FANG L, SZCZECH G: Phase I pharmacokinetic and safety evaluation of clevudine (L-FMAU), a new agent under development for the treatment of hepatitis B virus (HBV) infection. 40th ICAAC Abstracts (2000):19 (Abstract).
99. LEE H, MOMMEJA-MARIN H, SACKS SL et al.: A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in chronic HBV-infected patients (L-FMAU-102). 42nd ICAAC Abstracts (2002):434.
100. BLUM MR, HART R, SUMNERT, MOMMEJA-MARIN H, CHITTICK G: Evaluation of the potential drug interaction between clevudine and emtricitabine in healthy volunteers. 42nd ICAAC Abstracts (2002):27.
101. CHEN SH, WANG Q, MAO J et al.: Synthesis and biological evaluation of a series of 2′-fluorinated-2′,3′-dideoxy-2′,3′-didehydro-(L)-nucleosides. Bioorg. Med. Chem. Lett. (1998) 8:1589-1594.
102. ZHU YL, DUTSCHMAN DE, LIU SH, BRIDGES EG, CHENG YC: Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5-fluorocytidine. Antimicrob. Agents Chemother. (1998) 42:1805-1810.
103. PATEL J, MITRA AK: ACH-126443 Achillion/Yale University. Curr. Opin. Investig. Drugs (2002) 3:1580-1584.
104. LE GUERHIER F, PICHOUD C, JAMARD C et al.: Antiviral activity of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob. Agents Chemother. (2001) 45:1065-1077.
105. LE GUERHIER F, PICHOUD C, GUERRET S et al.: Characterization of the antiviral effect of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. (2000) 44:111-122.
106. DUNKLE LM, OSHANA SC, DICKSON J, CHENG YC, RICE WG: Phase I safety and pharmacokinetics of ACH-126,443, a potent anti-HIV and HBV nucleoside. 41st ICAAC, Chicago, IL, USA (2001).
107. AFDHAL N, O'BRIEN C, OSHANA SC, DUNKLE LM: Rapid, potent anti-HBV activity of ACH-126,443 in a phase I/II trial in chronic hepatitis B infection. 42nd ICAAC Abstract (2002):434.
108. DUNKLE LM: Elvucitabine: A potent nucleoside for treatment of multi-drug resistant hepatitis B and HIV. 16th ICAR Pre-conference satellite symposium 'Clinical Update on Antiviral Drugs', Savannah, GA, USA (2003).
109. ERION MD, COLBY TJ, REDDY KR et al.: Hepdirect™ prodrugs: A novel strategy for targeting drugs to the liver. Hepatology (2002) 36:301A.
110. HONG Z: Hepavir B: A safer and liver-targeting prodrug of PMEA. 4th International Antiviral Drug Discovery and Development Summit. Princeton, NJ, USA (2003).
111. HONG Z: Clinical development of hepavir B: A liver targeting prodrug of PMEA. 16th ICAR Pre-conference satellite symposium 'Clinical Update on Antiviral Drugs', Savannah, GA, USA (2003).
112. NOWAK MA, BONHOEFFER S, HILL AM et al.: Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA (1996) 93:4399-4402.
113. DELANEY WE: Development of a novel therapy for chronic hepatitis B: adefovir dipivoxil. 4th International Antiviral Drug Discovery and Development Summit, Princeton, NJ, USA (2003).
114. ZOULIM F, WERLE B, WURSTHORN K et al.: Quantitative analyses of hepatic HBV cccDNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: Results of an international multicenter study. Antiviral Res. (2003) 57:A43.